Genmab A (GMAB) Non Operating Interest Expenses (2019 - 2026)

Genmab A (GMAB) has reported Non Operating Interest Expenses for 8 consecutive years, with -$139.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 3.73% year-over-year to -$139.0 million; the trailing twelve-month figure through Jun 2026 stood at -$593.0 million (up 8.91% YoY), and the FY2025 full-year result was $269.0 million, down 7.56% from the prior year.
• Non Operating Interest Expenses climbed to -$139.0 million in Q2 2026 per GMAB's latest filing, from -$150.0 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at -$34.6 million in Q2 2022 and bottomed at -$435.0 million in Q1 2023.
• Historically, Non Operating Interest Expenses has averaged -$145.8 million across 5 years, with a median of -$136.5 million in 2025.
• The widest YoY moves for Non Operating Interest Expenses: up 91.95% in 2024, down 341.46% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at -$34.6 million in 2022, then sank by 634.97% to -$254.0 million in 2023, then decreased by 14.57% to -$291.0 million in 2024, then jumped by 41.58% to -$170.0 million in 2025, then climbed by 18.24% to -$139.0 million in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered -$139.0 million, -$150.0 million, and -$170.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.